Boathouse Capital Exits Versalinx in Sale to Questex

Boathouse Capital is pleased to announce that it has exited Versalinx via a sale to MidOcean Partners portfolio company, Questex. Questex, a leading information and events provider in the healthcare and life sciences sector, will leverage Versalinx's deep expertise in pharmaceutical events to expand its life sciences portfolio. The acquisition supports Questex's growth strategy in fast-evolving, high-growth industries and further strengthens its global healthcare and life sciences platform, enabling broader audience access and helping customers reach new markets more effectively.

Versalinx, a global provider of B2B events in the pharmaceutical industry with a specialized focus on research insights and competitive intelligence has been part of Boathouse Capital's portfolio since 2018 when it was acquired by Ducker Carlisle. Versalinx has built a reputation for connecting senior leaders and decision-makers across the U.S. and Europe through meaningful, content-rich environments that foster collaboration and innovation across the life sciences sector.